company background image
GALD logo

Galderma Group SWX:GALD Stock Report

Last Price

CHF 118.54

Market Cap

CHF 28.4b

7D

4.3%

1Y

n/a

Updated

06 Feb, 2025

Data

Company Financials +

GALD Stock Overview

Operates as a dermatology company worldwide. More details

GALD fundamental analysis
Snowflake Score
Valuation3/6
Future Growth4/6
Past Performance0/6
Financial Health4/6
Dividends0/6

My Notes

Capture your thoughts, links and company narrative

Galderma Group AG Competitors

Price History & Performance

Summary of share price highs, lows and changes for Galderma Group
Historical stock prices
Current Share PriceCHF 118.54
52 Week HighCHF 119.56
52 Week LowCHF 60.00
Beta0
1 Month Change12.04%
3 Month Change42.17%
1 Year Changen/a
3 Year Changen/a
5 Year Changen/a
Change since IPO85.22%

Recent News & Updates

Is There An Opportunity With Galderma Group AG's (VTX:GALD) 50% Undervaluation?

Dec 18
Is There An Opportunity With Galderma Group AG's (VTX:GALD) 50% Undervaluation?

Recent updates

Is There An Opportunity With Galderma Group AG's (VTX:GALD) 50% Undervaluation?

Dec 18
Is There An Opportunity With Galderma Group AG's (VTX:GALD) 50% Undervaluation?

These 4 Measures Indicate That Galderma Group (VTX:GALD) Is Using Debt Reasonably Well

Oct 27
These 4 Measures Indicate That Galderma Group (VTX:GALD) Is Using Debt Reasonably Well

Shareholder Returns

GALDCH PharmaceuticalsCH Market
7D4.3%4.4%0.1%
1Yn/a19.2%9.7%

Return vs Industry: Insufficient data to determine how GALD performed against the Swiss Pharmaceuticals industry.

Return vs Market: Insufficient data to determine how GALD performed against the Swiss Market.

Price Volatility

Is GALD's price volatile compared to industry and market?
GALD volatility
GALD Average Weekly Movement3.5%
Pharmaceuticals Industry Average Movement2.9%
Market Average Movement3.6%
10% most volatile stocks in CH Market8.3%
10% least volatile stocks in CH Market1.6%

Stable Share Price: GALD has not had significant price volatility in the past 3 months compared to the Swiss market.

Volatility Over Time: GALD's weekly volatility (4%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
19816,545Flemming Ornskovwww.galderma.com

Galderma Group AG operates as a dermatology company worldwide. The company delivers a science-based portfolio of brands and services that span the spectrum of the dermatology market, including injectable aesthetics, dermatological skincare, and therapeutic dermatology. Its portfolio of flagship brands includes Dysport/Azzalure, Alluzience, Restylane, and Sculptra in injectable aesthetics; Cetaphil and Alastin in dermatological skincare; and Soolantra, Epiduo, Differin, Aklief, Epsolay, Twyneo, Oracea, Metvix, Benzac, and Loceryl in therapeutic dermatology.

Galderma Group AG Fundamentals Summary

How do Galderma Group's earnings and revenue compare to its market cap?
GALD fundamental statistics
Market capCHF 28.40b
Earnings (TTM)-CHF 12.85m
Revenue (TTM)CHF 3.91b

7.2x

P/S Ratio

-2,191x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
GALD income statement (TTM)
RevenueUS$4.32b
Cost of RevenueUS$1.31b
Gross ProfitUS$3.00b
Other ExpensesUS$3.02b
Earnings-US$14.20m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

Mar 06, 2025

Earnings per share (EPS)-0.06
Gross Margin69.54%
Net Profit Margin-0.33%
Debt/Equity Ratio37.1%

How did GALD perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/02/06 20:01
End of Day Share Price 2025/02/06 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Galderma Group AG is covered by 14 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Bethan DaviesBerenberg
Richard ParkesBNP Paribas Exane
Joffrey MellerBofA Global Research